Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
SEC Accession No. 0001104659-25-061301
Filing Date
2025-06-23
Accepted
2025-06-23 06:02:04
Documents
4

Document Format Files

Seq Description Document Type Size
1 SC TO-T/A tm2516065d11_sctota.htm SC TO-T/A 23560
2 EXHIBIT (A)(5)(E) tm2516065d11_ex99-a5e.htm EX-99.(A)(5)(E) 16817
3 GRAPHIC tm2516065d11_ex99-a5eimg2.jpg GRAPHIC 6870
4 GRAPHIC tm2516065d11_ex99-a5eimg1.jpg GRAPHIC 8462
  Complete submission text file 0001104659-25-061301.txt   63497
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Filed by) CIK: 0001114448 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC TO-T/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Subject) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC TO-T/A | Act: 34 | File No.: 005-87002 | Film No.: 251062846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)